| Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation MK Liszewski, M Kolev, G Le Friec, M Leung, PG Bertram, AF Fara, ... Immunity 39 (6), 1143-1157, 2013 | 578 | 2013 |
| EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis DM Gerlag, K Raza, LGM Van Baarsen, E Brouwer, CD Buckley, ... Annals of the rheumatic diseases 71 (5), 638-641, 2012 | 539 | 2012 |
| T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells G Arbore, EE West, R Spolski, AAB Robertson, A Klos, C Rheinheimer, ... Science 352 (6292), aad1210, 2016 | 515 | 2016 |
| Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence B Russell, C Moss, G George, A Santaolalla, A Cope, S Papa, ... ecancermedicalscience 14, 2020 | 501 | 2020 |
| Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases AP Cope, D Gibbons, FM Brennan, M Feldmann, D Aderka, M Doherty, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1992 | 436 | 1992 |
| Treg cells suppress osteoclast formation: a new link between the immune system and bone MM Zaiss, R Axmann, J Zwerina, K Polzer, E Gückel, A Skapenko, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2007 | 414 | 2007 |
| The central role of T cells in rheumatoid arthritis AP Cope, H Schulze-Koops, M Aringer Clinical and experimental rheumatology 25 (5), S4, 2007 | 411 | 2007 |
| Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling AP Cope, RS Liblau, XD Yang, M Congia, C Laudanna, RD Schreiber, ... The Journal of experimental medicine 185 (9), 1573-1584, 1997 | 345 | 1997 |
| The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells S Jones, N Horwood, A Cope, F Dazzi The Journal of Immunology 179 (5), 2824-2831, 2007 | 331 | 2007 |
| Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells J Cardone, G Le Friec, P Vantourout, A Roberts, A Fuchs, I Jackson, ... Nature immunology 11 (9), 862-871, 2010 | 315 | 2010 |
| Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in … AP Cope, M Londei, NR Chu, SB Cohen, MJ Elliott, FM Brennan, ... The Journal of clinical investigation 94 (2), 749-760, 1994 | 302 | 1994 |
| The Th1 life cycle: molecular control of IFN-γ to IL-10 switching A Cope, G Le Friec, J Cardone, C Kemper Trends in immunology 32 (6), 278-286, 2011 | 300 | 2011 |
| Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? GL Burn, L Svensson, C Sanchez-Blanco, M Saini, AP Cope FEBS letters 585 (23), 3689-3698, 2011 | 283 | 2011 |
| Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation V Nicolaidou, MM Wong, AN Redpath, A Ersek, DF Baban, LM Williams, ... PloS one 7 (7), e39871, 2012 | 281 | 2012 |
| A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis K Bechman, S Subesinghe, S Norton, F Atzeni, M Galli, AP Cope, ... Rheumatology 58 (10), 1755-1766, 2019 | 276 | 2019 |
| The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU) AD Dick, JV Forrester, J Liversidge, AP Cope Progress in retinal and eye research 23 (6), 617-637, 2004 | 250 | 2004 |
| Innate-like T cells straddle innate and adaptive immunity by altering antigen-receptor responsiveness M Wencker, G Turchinovich, R Di Marco Barros, L Deban, A Jandke, ... Nature immunology 15 (1), 80-87, 2014 | 241 | 2014 |
| Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 … A Tyndall, UA Walker, A Cope, F Dazzi, C De Bari, W Fibbe, S Guiducci, ... Arthritis research & therapy 9, 1-10, 2007 | 234 | 2007 |
| EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors M Kostine, A Finckh, CO Bingham, K Visser, J Leipe, H Schulze-Koops, ... Annals of the rheumatic diseases 80 (1), 36-48, 2021 | 225 | 2021 |
| Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus D Aderka, A Wysenbeek, H Engelmann, AP Cope, F Brennan, Y Molad, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1993 | 222 | 1993 |
